Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.3K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

975
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
975
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.8K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.8K
Protein-protein Interfaces02:04

Protein-protein Interfaces

14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A cytosolic class I small heat shock protein, RcHSP17.8, of Rosa chinensis confers resistance to a variety of stresses to Escherichia coli, yeast and Arabidopsis thaliana.

Plant, cell & environment·2009
Same author

Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.

Neurochemistry international·2009
Same author

[Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2009
Same author

Anti-hypoxic activity of the ethanol extract from Portulaca oleracea in mice.

Journal of ethnopharmacology·2009
Same author

[Effects of artemether and dihydroarteannuin on mouse model of scleroderma].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2009
Same author

Astragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats.

European journal of pharmacology·2009

相关实验视频

Updated: Jan 15, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

一个超图卷积网络,具有明确的高阶交互信息提取,用于药物重新定位.

Xiang Du, Xinliang Sun, Min Zeng

    IEEE transactions on computational biology and bioinformatics
    |October 8, 2025
    PubMed
    概括

    这项研究介绍了HGCNDR,这是一种用于药物重新定位的新型超图卷积网络. 它有效地建模了高阶相互作用,以确定新的药物疾病关联,在预测中超越现有方法.

    科学领域:

    • 计算生物学是一种计算生物学.
    • 药物发现 药物发现
    • 生物信息学是一种生物信息学.

    背景情况:

    • 药物重新定位通过为现有药物找到新的用途,降低成本和风险,加速药物开发.
    • 超图神经网络 (HGNNs) 越来越多地用于药物重新定位,因为它们能够建模复杂的关系.
    • 现有的HGNN方法往往无法充分捕捉各种关系和高阶相互作用.

    研究的目的:

    • 提出HGCNDR,一个设计用于药物重新定位中的明确高阶相互作用提取的超图卷积网络.
    • 加强对药物和疾病之间多样化的关系和高阶相互作用的建模.
    • 提高识别新型药物疾病关联的准确性和效率.

    主要方法:

    • 开发了HGCNDR,结合了关系意识的超图卷积和哈达马德产品战略,用于高阶交互.
    • 使用药物/疾病相似性和关联网络构建特征图和超图.
    • 用于特征图嵌入的图形卷积网络 (GCN) 和用于超图嵌入的专业操作.
    • 引入了一种一致性约束,以保持嵌入式之间的语义共同点.

    主要成果:

    • HGCNDR在与几种已建立的基线方法相比,表现出了竞争力.
    • 实验结果表明,在检索实际药物与疾病的关联方面,他们有更好的能力.

    更多相关视频

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
    07:51

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

    Published on: May 21, 2018

    12.5K
    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    19.5K

    相关实验视频

    Last Updated: Jan 15, 2026

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.2K
    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
    07:51

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

    Published on: May 21, 2018

    12.5K
    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    19.5K
  • 对阿尔茨海默病和乳腺癌的案例研究证实了该方法的预测能力.
  • 结论:

    • HGCNDR通过明确建模高阶相互作用,有效地解决了现有的HGNN药物重新定位方法的局限性.
    • 拟议的模型显示出在确定现有药物的新疗法应用方面具有显著的前景.
    • HGCNDR为加速药物发现和开发管道提供了一个有价值的工具.